Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat—possible involvement of kynurenic acid by Thaler, Sebastian et al.
BASIC SCIENCE
Neuroprotection by acetoacetate and β-hydroxybutyrate
against NMDA-induced RGC damage in rat—possible
involvement of kynurenic acid
Sebastian Thaler & Tomasz J. Choragiewicz & Robert Rejdak & Michal Fiedorowicz &
Waldemar A. Turski & Maria Tulidowicz-Bielak & Eberhart Zrenner &
Frank Schuettauf & Tomasz Zarnowski
Received: 29 October 2009 /Revised: 29 March 2010 /Accepted: 20 May 2010 /Published online: 8 June 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose This study investigated the effects of systemically
administered lithium acetoacetate (ACA) and sodium β-
hydroxybutyrate (BHB) in a rat model of N-methyl-D-
aspartate (NMDA)-induced damage of retinal ganglion cells
(RGC). Additionally, the influence of ACA and BHB on
kynurenic acid (KYNA) production was assessed in vitro in
bovine retinal slices.
Methods Female adult Brown–Norway rats in groups of 5–
8 animals were used. ACA and BHB were administered
intraperitoneally once a day for 21 consecutive days, and
phosphate buffered saline (PBS) was administered to
control animals. After 2 weeks, the animals received
intraocular NMDA (2 μl of a 10 mM solution in PBS) or
intraocular PBS as a control. On day 19, retinal ganglion
cells were labeled retrogradely with hydroxystilbamidine.
Two days later, RGC density (cells per mm
2) was assessed
on retinal flatmounts. Additionaly, bovine retinal slices
were incubated with NMDA and ACA or BHB at
concentrations of 1.0 mM and 3.0 mM, and de novo
KYNA production was measured using HPLC.
Results Intraperitoneal ACA (250 mg/kg) or BHB
(291.2 mg/kg) significantly protected RGC against
NMDA-induced neurodegeneration. De novo KYNA pro-
duction in bovine retinal slices was lowered by NMDA.
Both ACA and BHB at a concentration of 3.0 mM
significantly reduced the effects of NMDA.
Conclusions ACA and BHB had a significant dose-
dependent neuroprotective effect on RGC in a rat model
of NMDA-induced RGC damage. Both ketone bodies also
significantly attenuated NMDA-induced reduction of retinal
KYNA production in vitro, suggesting that this mechanism
may be essential for the neuroprotective effects of ACA and
BHB in vivo. Our results imply that ketone bodies may
represent an additional treatment option in chronic neuro-
degenerative disorders of the eye.
Keywords β-hydroxybutyrate.Acetoacetate.Retinal
ganglion cells.Kynurenic acid.Neuroprotection
Introduction
The anticonvulsant effects of ketogenic diets have been
clinically used for decades in the treatment of epilepsy (see
[1] for a review). In recent years, accumulating evidence
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A ketogenic diet consists of a high fat content (80–90%)
with little, but sufficient protein and insufficient carbohy-
drates for normal metabolism. Under a ketogenic diet, fat is
metabolized in the liver into the ketone bodies acetoacetate
(ACA), β-hydroxybutyrate (BHB) and acetone, thus pro-
viding an alternative energy source for glucose. The
production of ketone bodies is especially important in brain
metabolism, which under normal circumstances depends
mainly on glucose. In contrast to fatty acids, ketone bodies
can cross the blood-brain barrier—in the case of BHB and
ACA with the help of monocarboxylate transporters [2].
In recent years, several studies have shown neuro-
protective properties of the ketone bodies BHB and ACA
in experimental models of neurodegenerative diseases of
the brain, in particular Parkinson’s disease or Alzheimer’s
disease but also in traumatic brain injury or cerebral
hypoxia [3–8].
It is of importance that crucial pathways leading to
deceleration of neuronal degeneration in chronic neurode-
generative diseases of other brain regions, i.e., Alzheimer’s
or Parkinson’s disease, share similar characteristics with
neurodegenerative diseases of the retina, e.g., glaucoma,
diabetic retinopathy, ischemia, and secondary degeneration
after optic nerve trauma. Glutamate-related excitotoxicity
has been implicated as a key contributing factor in different
neurodegenerative disorders of the brain (see [9] for a
review) including glaucomatous retinal ganglion cell
(RGC) loss or in retinal ischemia [10, 11]. Excitotoxic
damage is thought to be mediated partly by overstimulation
of N-methyl-D-aspartate (NMDA)-type glutamate recep-
tors, leading to intracellular Ca
2+ elevation and consecu-
tively to mitochondrial dysfunction and an excess of free
radical formation [12]. Increase of oxidative stress and
nitric oxide derived (nitrosative) stress has been shown to
play an important role in experimental models of glaucoma
and other neurodegenerative diseases [13–15].
Notably, ketone bodies can exert effective neuroprotec-
tion in different models of neuronal excitotoxicity and
ischemia [4, 16]. Although the underlying mechanisms are
not fully understood, both an elevation of ATP production
via Kreb’s cycle, and mitochondrial membrane stabiliza-
tion, seem to play an important role [17, 18]. Other highly
interesting possibilities include enhancement of antioxida-
tive mechanisms and modulation of endogenous neuro-
protectants, in particular kynurenic acid (KYNA), an
excitatory amino acid antagonist [19].
In the present study, we tested the effects of the
systemically applied ketone bodies ACA and BHB on the
survival of RGC in a rat model with NMDA-induced
excitotoxic RGC damage. We also evaluated the effects of
ACA and BHB on de novo production of KYNA in bovine
retinas. To our knowledge, this is the first time that effects
of ketone bodies in a retinal neurodegeneration model have
been systematically studied.
Material and methods
Animals
Adult female Brown–Norway rats (Charles River, Sulzfeld,
Germany) with a body weight (BW) of 150–200 g were
used. The animals were kept under a 12-hour light–dark
cycle with food and water ad libitum. All experiments were
performed in compliance with the ARVO (Association for
Research in Vision and Ophthalmology) statement for the
Use of Animals in Ophthalmic and Vision research.
Ketone bodies—intraperitoneal injections
The ketone bodies lithium acetoacetate (ACA) and sodium
β-hydroxybutyrate (BHB) (both Sigma-Aldrich, Munich,
Germany) were dissolved in 0.1 M phosphate buffered
saline (PBS, pH 7.4) to a concentration of 10% w/v as a
stock solution.
Intraperitoneal injections were performed once a day for
21 consecutive days on four treatment groups and one
control group (n=5–8): (1) ACA (62.5 mg/kg BW), (2)
ACA (250 mg/kg BW), (3) BHB (72.8 mg/kg BW), (4)
BHB (291.2 mg/kg BW), and (5) PBS alone.
NMDA injections
On day 14, animals received intravitreal injections of
NMDA versus PBS. Rats were anesthetized with an
intraperitoneal injection of chloral hydrate (7%, 6 ml/kg
BW). Single injections of 10 mM NMDA (Sigma-Aldrich,
Munich, Germany) in 0.1 M PBS (pH 7.4) were adminis-
tered intravitreally with a heat-pulled glass capillary
connected to a microsyringe (Drummond Scientific Co.,
Broomall, PA, USA) under direct observation through a
microscope. The capillary was inserted approximately
1 mm posterior to the corneal limbus at the temporal
inferior side (OD: eight o’clock position, OS: four o’clock
position). Animals with visible lens damage were excluded
from the experiments and not used thereafter. A single
injection of 2 μl NMDA was given. In each case, the
contralateral eye served as a control eye and was injected
with PBS.
Quantification of retinal ganglion cells
On day 19, retrograde labeling of RGC was performed.
Animals were anaesthetized with chloral hydrate, and 7 µl
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fonate (Fluorogold, Molecular Probes, Eugene, OR, USA)
was injected stereotaxically into each superior colliculus.
Two days later, the number of RGC (cells per mm
2)w a s
assessed. The animals were sacrificed with CO2; the eyes
were enucleated, and the retinas dissected, flat-mounted
on cellulose nitrate filters (pore size 60 m; Sartorius, Long
Island, NY) and fixed in 2% paraformaldehyde for 30 min.
Labeled cells were defined as surviving. Visualization of
RGC was performed on the same day by fluorescence
microscopy. Images obtained using a digital imaging
system (ImagePro 3.0, Media Cybernetics Inc., Silver
Spring, MD, USA) connected to a microscope were coded
and analyzed in a masked fashion. Three areas of
0.04 mm
2 each per retinal quadrant at three different
eccentricities of one-sixth, one-half, and five-sixths of the
retinal radius were counted, corresponding to 0.7 mm,
2.0 mm, and 3.3 mm distance from the optic nerve head at
the 45°, 135°, 225°, and 315° meridian [20]. Labeled cells
were thereby counted in 12 distinct areas of 62,500 µm
2
each in each retina. The data are presented as the mean
RGC count per mm
2 of retina±SEM, unless stated
otherwise.
KYNA production—in vitro
Assessment of de novo KYNA production was performed
using the method of Turski et al. [21]. Adult bovine eyes
were obtained from a local slaughterhouse up to 2 hours
post mortem (n=5–7). Briefly, their retinas were cut in
slices with a McIlwain tissue chopper and put on culture
wells containing 1 ml oxygenated Krebs-Ringer buffer, pH
7.4. Following 10 min of preincubation at 37°C, the tissues
were incubated with 25 μM L-kynurenine, 1–3m M
NMDA (leading to reduction of KYNA production by
40–60%, see also [22]) and 1.0 mM and 3.0 mM ACA or
BHB for 2 hours. ACA and BHB were added to the
incubation media 15 min before NMDA, and NMDA
15 min before L-kynurenine. Afterwards, the media were
separated from the tissue and applied to the cation-
exchange columns (Dowex 50
+W). KYNA was eluted with
2 ml water, and the eluate was subjected to high-
performance liquid chromatography (HPLC). KYNA was
detected fluorimetrically according to the method of
Shibata [23]. KYNA production was measured in pmol/
well.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 4.01 for Windows (GraphPad Software, San Diego,
CA, USA, www.graphpad.com). Analysis of variance
(ANOVA) was performed followed by Bonferroni’sm u l -
tiple comparisonpost-hoc test. Differences were regarded
significant when p <0.05. Unless stated otherwise, the
data are presented as means with respective standard
errors.
Results
Effect of NMDA on RGC
When injected intravitreally, NMDA reduced RGC
numbers from 2,364±37 cells/mm
2 (mean ± SEM; n =6;
PBS injected controls) to 217±6 cells/mm
2 (n =6)(Figs.1
and 2).
Effect of NMDA on RGC in ACA treated animals
RGC density in retinas collected from NMDA-injected
eyes after 21 days of treatment intraperitoneally with ACA
62.5 and 250 mg/kg was 190±14 cells/mm
2 (n =4) and
322±25 cells/mm
2 (n =5) respectively. The mean cell
count in rats treated with 250 mg/kg ACA was signifi-
cantly higher (p <0.001) than in the PBS-injected controls
(Figs. 1 and 2).
Effect of NMDA on RGC in BHB treated animals
RGC density in retinas collected from NMDA-injected eyes
after 21 days of treatment with intraperitoneally injected
BHB 72.8 and 291.2 mg/kg was 178±10 cells/mm
2 (n =5)
and 307±17 cells/mm
2 (n =5) respectively. The mean cell
count in eyes treated with BHB in a dose of 291.2 mg/kg
was significantly higher (p <0.01) than in the PBS-injected
controls (Figs. 1 and 2).
Effect of ACA and BHB on RGC in control animals
Neither ACA nor BHB treatment affected RGC density in
PBS-injected eyes. RGC density in retinas collected from
PBS-injected eyes was 2328±60 cells/mm
2 (n =5) for
ACA-treated rats and 2310±51 cells/mm
2 (n =5) for BHB-
treated rats.
Effect of ACA on KYNA production in bovine retinal
slices
NMDA decreased de novo production of KYNA to 41.2%
(p <0.001) of that in controls. ACA 3.0 mM significantly
countered this: KYNA production after NMDA remained at
75.3% of that in controls (p <0.001). However, ACA 1.0
was ineffective in this respect. Incubation of retinal slices
with ACA 1.0 or 3.0 mM without NMDA did not change
KYNA production (Fig. 3).
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slices
NMDA decreased de novo production of KYNA to 60.3%
(p <0.01) of that in controls, but BHB 3.0 mM provided
complete protection against NMDA-induced inhibition of
KYNA production (p <0.001). BHB 1.0 mM was ineffec-
tive in this respect. Incubation of retinal slices with BHB
1.0 or 3.0 mM without NMDA did not change KYNA
production (Fig. 4).
Discussion
Ketogenic diets have been used for over 80 years in the
treatment of epilepsy. Recently, neuroprotective properties
of ketone bodies have been found in diverse models of such
neurodegenerative diseases of the brain as Parkinson’so r
Alzheimer’s disease, and in models of brain trauma,
hypoxia or ischemia [3–8]. To date, however, similar
studies regarding retinal degeneration have not been
performed.
Fig. 2 RGC numbers 7 days after intraocular NMDA injections in
systemically ACA- and BHB-treated animals, PBS served as control
(n =6). ACA was used in the following doses: 250 mg/kg in PBS-
treated eyes (n =5); 62.5 mg/kg (n =4) or 250 mg/kg (n =5) in
NMDA-treated eyes. BHB was used in the following doses: 291.2 mg/
kg in PBS-treated eyes (n =5); 72.8 mg/kg (n =5) or 291.2 mg/kg
(n =5) in NMDA-treated eyes. ** p <0.01; *** p <0.001
Fig. 1 Retinal flatmounts of rat retinas. RGCs were backlabeled with
the fluorescent marker hydroxystilbamidine. a Control, no NMDA. b-
f Seven days after intraocular injection of NMDA in groups
intraperitoneally treated with (b) PBS as control, (c) ACA 62.5 mg/
kg, (d) ACA 250 mg/kg, (e) BHB 72.8 mg/kg and (f) BHB 291.2 mg/
kg. Retinal area of images a-f: 2 mm from the optic nerve head, nasal
inferior or superior quadrants. Scale bar, 50 µm
1732 Graefes Arch Clin Exp Ophthalmol (2010) 248:1729–1735Excitotoxicity, which contributes to free radical forma-
tion and neuronal cell death, is an important factor in
diverse chronic neurodegenerative diseases in the brain and
also in the retina [4]. Excitatory neurotoxicity is mediated
in part by overactivation of the NMDA-type glutamate
receptor [12]. In the present study, an excitotoxic rat model
of NMDA-induced RGC damage [24] was used to evaluate
the neuroprotective properties of systemic application of the
ketone bodies ACA and BHB in the retina.
In rats, a single intravitreal NMDA injection reduced the
RGC number to around 10% of that in PBS-injected
controls. This RGC loss is comparable to that found in
other studies using NMDA-induced retinal degeneration
[25, 26].
However, ACA and BHB ameliorated the cell damage
induced by NMDA, and resulted in a relative RGC increase
of 48.4% and 41.5% respectively when administered
intraperitoneally for 21 days.
It is possible that the lithium fraction in the lithium salt
of ACA leads to neuroprotective effects, as shown
previously in a rat model of partial optic nerve crush.
However, the amount of lithium in doses of ACA as high as
250 mg/kg is less than that which showed a significant
neuroprotective effect in previous studies of the retina [27].
Furthermore, Massieu et al. demonstrated a protective effect
of the lithium salt of ACA (250 mg/kg i.p.) but not of the
lithium fraction alone in a model of glutamate-mediated
neuronal damage in the hippocampus [4]. Although an
additive effect of lithium and ACA cannot be excluded, a
substantial modification of ACA’s effects by the lithium
fraction seems unlikely. Moreover, the neuroprotective
effect of BHB against RGC death was comparable to that
of ACA, even though BHB is not a lithium compound.
Two other studies found similar results for ACA but not
for BHB in vivo, whereas the effective dose of intraperi-
toneal ACA after glutamate-mediated neuronal damage in
the hippocampus was the same as in our study [4, 28], BHB
at 332 mg/kg failed to achieve a neuroprotective effect [28].
In contrast, another study on glutamate-mediated neuronal
damage showed reduced levels of lipoperoxidation after a
single intraperitoneal injection of 500 mg/kg BHB [29], and
Suzuki et al. demonstrated prolonged survival times after
intravenous application of 30 mg/kg BHB in a rat model of
brain anoxia [6]. In all these studies, however, treatment
times were shorter than in our study.
Plasma levels of ACA and BHB in rats have been shown
to be increased from 0.06 mM (controls) to 0.6 mM 10
minutes after a single injection of 500 mg/kg ACA or BHB
[29]. However, in vitro considerably higher concentrations
(5 mM ACA and 4 mM BHB) were the most effective
against glutamate toxicity in a mouse hippocampal cell line
[16], in good agreement with our in vitro results in bovine
retinal tissue.
How ketone bodies confer their neuroprotective effect on
neuronal cells remains unclear, and several theories are
currently under discussion. An important underlying mech-
anism may be an increase in neuronal stability due to
enhanced ATP production [30, 31]. In accordance with this
theory, Bough et al. found an increased number of
mitochondrial profiles in rats fed a ketogenic diet, suggest-
ing a stimulation of mitochondrial biogenesis and a higher
phosphocreatine/creatine ratio in the hippocampus and
higher available energy reserves [32]. Such an increased
energy level of the neurons might ensure them a better
supply of the Na/K-ATPase, leading to enhanced membrane
stability, and thus providing an improved resistance to
metabolic stress.
Fig. 4 Effect of BHB on de novo KYNA production in bovine retinal
slices. Data is given as percentage of positive control. Control slices
(n =6) were incubated with 25 µM L-kynurenine alone. NMDA-
treated slices (n =6) were incubated with 25 µM L-kynurenine and
1.0 mM NMDA. BHB was used at concentrations of 1.0 and 3.0 mM
alone (n =6 for both groups) or in combination with 1.0 mM NMDA
(n =6 for both groups). 100%=3.1 pmol. ** p <0.01; *** p <0.001
Fig. 3 Effect of ACA on de novo KYNA production in bovine retinal
slices. Data is given as percentage of control. Control slices (n =6)
were incubated with 25 µM L-kynurenine alone. NMDA treated slices
(n =6) were incubated with 25 µM L-kynurenine and 3.0 mM
NMDA. ACA was used at concentrations of 1.0 and 3.0 mM alone
(n =8 and n =6 respectively) or in combination with 3.0 mM NMDA
(n =5 and n =6 respectively). 100%=8.0 pmol. *** p <0.001
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diet or ketone bodies against excitotoxic neuronal degener-
ation, and proposed that oxidative stress modulation rather
than glutamate receptor modulation may be important for
this effect [4, 16, 28, 33]. Direct interaction of ketone
bodies with glutamate receptors has been shown only for L-
BHB (voltage-dependent blockade of NMDA receptors),
whereas ACA or D-BHB were not able to reduce NMDA,
AMPA or Kainate receptor-induced currents [34, 35].
Furthermore, even though ACA has been demonstrated to
have a protective effect in hippocampal cells, this protective
effect was also found in cells which lacked glutamate
receptors [16]. Such neuroprotective effects are probably
due indirectly to an enhancement of cellular antioxidant
capacity. Several studies describe an influence of ketone
bodies on different antioxidative mechanisms of neuronal
cells. Veech et al. showed that BHB is able to oxidize
co-enzyme Q and reduce NADP+, thus reducing free
radical formation [36]. In addition, the reduction of
mitochondrial free radical formation resulting from an
increase the NAD
+/NADH ratio, along with the scaveng-
ing capacities of ACA and BHB for diverse reactive
oxygen species (ROS), may contribute to neuroprotective
effects, even when increase in oxidative stress is increased
by excitotoxicity [29, 37].
Other factors which possibly play a role here include
upregulation of glutathione peroxidase activity, an enzyme
that can prevent lipid peroxidation, and upregulation of
calbindin [33, 38, 39].
In addition to an indirect influence on glutamate-induced
neurotoxicity via the antioxidant effects of ketogenic diet or
ketone bodies, indirect glutamate receptor modulation via
reversal of the NMDA-inhibiting effect on the production
of KYNA, an endogenous NMDA receptor modulator, has
been postulated, and may play an additional role in
preventing glutamate-induced neurotoxicity [19, 40]. In
our study, NMDA-induced reduction of de novo KYNA
production in ACA- and BHB-incubated bovine retinas in
vitro was significantly attenuated. This effect was much
more pronounced than the increase in RGC numbers after
treatment with ketone bodies in vivo; therefore, a sole
survival effect of KYNA-producing cells in the in vitro
setting seems rather unlikely. The in vivo situation,
however, is not directly comparable to the in vitro setting;
further studies have to show in detail how ketone bodies
modify KYNA production in the context of excitotoxicity.
Modulation of NMDA receptors via alteration of KYNA-
levels is especially of therapeutic interest. Since NMDA
receptors are essential for neuronal transmission, a full
blockade of NMDA receptors would not be suitable for
clinical application; rather, it would be preferable to prevent
receptor overstimulation while reducing free radical forma-
tion [41, 42]. Ketone bodies therefore seem to offer
interesting features for treatment or prevention of cellular
damage in different neuronal degenerations.
This study showed for the first time that systemically
applied ketone bodies exert a partial neuroprotective action
against NMDA-induced RGC damage in rats. Moreover,
ACA and BHB were found to attenuate NMDA-induced
inhibition of KYNA production in retinas in vitro. We
believe that the use of ketone bodies or ketogenic diets
should be considered and further evaluated in the quest for
effective therapeutic approaches in the treatment of retinal
degenerations.
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